No Prescription |
 |
 | ||
|
Sibelium Generic Flunarizine |
|
| ||
No Prescription » Prescription Drugs 15 » Sibelium Generic Flunarizine SIBELIUM is indicated in:û Prophylaxis of classic (with aura) or common (without aura) migraine. û Symptomatic treatment of vestibular vertigo (due to a diagnosed functional disorder of the vestibular system). DOSAGE AND DIRECTIONS FOR USEMigraine ProphylaxisStarting Dose:Two 5 mg capsules (10 mg) SIBELIUM at night in patients less than 65 years of age and 5 mg daily in patients older than 65 years. If during this treatment depressive extrapyramidal or other unacceptable symptoms occur administration should be discontinued. If after 2 months of this initial treatment no significant improvement is observed the patient should be considered a non-responder and administration should be discontinued.Maintenance Treatment:If a patient is responding satisfactorily and if a maintenance treatment is needed the dose should be decreased to 5 days treatment at the same daily dose with two successive medicine free days every week.Even if the prophylactic maintenance treatment is successful and well tolerated it should be interrupted after 6 months and it should be re-initiated only if the patient relapses.VertigoThe same dosage should be used as for migraine but the starting treatment should not be given longer than needed for symptom control which generally takes less than two months.After one month of treatment for chronic vertigo or after two months treatment for paroxysmal vertigo no significant improvement is observed the patient should be considered a non-responder and administration should be discontinued. Buy Sibelium Generic Flunarizine and other Prescription Drugs 15 products online at Medstore. Buy Online at Medstore - Click Here!
About Sibelium Generic Flunarizine: Product Type: Prescription Drugs 15 Sibelium (Generic Flunarizine) Sibelium (Generic Flunarizine) Generic Flunarizine 10mg Generic Flunarizine Sibelium
View more Prescription Drugs 15 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
